Prévisions
L'objectif de cours moyen des analystes est de 27,80 € (+309,43 %). La médiane est de 27,80 € (+309,43 %).
| Acheter |
12 |
| Conserver |
5 |
| Vendre |
4 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Arcturus Therapeutics presents pipeline at Cantor conference; pivotal data expected soon
Arcturus Therapeutics presented three core programs at the Cantor Global Healthcare Conference: ARCT-810 for OTC deficiency, an inhaled mRNA program for cystic fibrosis (CF), and a self-amplifying mRNA platform with commercial vaccine success. Near-term catalysts include the Phase II readout for ARCT-810 expected later this month, FDA feedback, and a fourth-quarter decision on whether to continue the CF program — a move that could trigger funding from Thermo Fisher. Management highlights technological advantages (biodegradable LNPs, improved mRNA purification, a tailored nebulizer) but still sees risks around efficacy, safety and competition. » Plus sur de.investing.com
Arcturus Therapeutics sees 2026 as a turning point with two near-term catalysts
At the Citigroup conference, Arcturus Therapeutics announced two near-term catalysts: Phase II data on OTC deficiency in September and a go/no-go decision on initiating Phase III for cystic fibrosis in the fourth quarter. The inhaled mRNA platform was presented as differentiated after safety and tolerability issues were addressed. Thermo Fisher has committed up to $40 million to non-dilutively support the Phase III cystic fibrosis development in exchange for exclusive manufacturing rights. The vaccine business provides non-dilutive revenue to fund the therapeutic pipeline; substantial CF data are expected in early 2025. » Plus sur de.investing.com
Arcturus Therapeutics jumps after management signal and conference announcements
Arcturus Therapeutics’ stock rose intraday by about 10–13% after management announced participation in five major investor conferences in September, viewed as a vote of confidence in the pipeline. Key clinical milestones for ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency) are approaching. Analyst support, better-than-expected quarterly results, more than $191 million in cash and a strategic manufacturing agreement with Thermo Fisher bolster the funding outlook through 2028 and the credibility for a potential phase 3 study. The rally occurred despite a weaker broader market and appears to be company-specific. » Plus sur de.investing.com
Arcturus highlights strong liquidity and upcoming clinical catalysts
Arcturus has more than $200 million in liquidity, giving it a funding runway into 2028 to support development of its programs. The company expects a Q4 2024 decision on advancing ARCT-032 (inhaled mRNA for cystic fibrosis) into phase III and anticipates data and regulatory guidance for ARCT-810 (OTC deficiency) before Sept. 30, 2024. The vaccine business, including KOSTAIVE (approved in 32 countries), has been returned to 100% strategic control and is intended to help fund the therapeutics pipeline. Arcturus is evaluating partnerships and has outlined a possible $40 million support from Thermo Fisher tied to a phase III decision. » Plus sur de.investing.com
Arcturus Therapeutics reduces quarterly loss more than expected despite 89% revenue drop
Arcturus reported an adjusted loss of $0.84 per share in Q2 versus a consensus expectation of $1.05, beating estimates by 20%. Revenue fell to $2.96 million, a decline of 89.4% year‑on‑year after the end of the collaboration with CSL Seqirus. Cash and equivalents amounted to $191.5 million, securing a liquidity runway of more than 2.5 years. The company cut R&D spending, is advancing cystic fibrosis (ARCT‑032) and OTCD (ARCT‑810) programs, and expects Phase II/III decisions and data in the second half of 2026. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursEn 2012, Arcturus Therapeutics a déjà versé 2,66 € de dividendes. Le dernier versement a eu lieu en décembre 2012.
Données financières
Au dernier trimestre, Arcturus Therapeutics a réalisé un chiffre d'affaires de 16,15 M € et un bénéfice net de -6,55 M €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 16,15 M | 10,53 % |
| Bénéfice brut | 16,15 M | 37,28 % |
| Bénéfice net | -6,55 M | 42,88 % |
| EBITDA | -6,55 M | 39,45 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 211,19 M € |
Nombre d'actions | 28,82 M |
Plus haut/bas sur 52 semaines | 16,37 € - 5,01 € |
| Dividendes | Non |
Bêta | 2,61 |
Ratio P/E | -2,59 |
Ratio PEG | 0,10 |
Ratio P/B | 1,36 |
Ratio P/S | 9,29 |
Profil de l'entreprise
Arcturus Therapeutics Holdings Inc., une entreprise de médicaments à base d'ARN, se concentre sur le développement de vaccins contre les maladies infectieuses, ainsi que de traitements contre les maladies rares du foie et des voies respiratoires aux États-Unis. Les programmes de développement de la société comprennent le programme LUNAR-OTC pour le déficit en ornithine transcarbamylase (OTC) ; et le programme LUNAR-CF pour la maladie pulmonaire de la mucoviscidose causée par des mutations du gène du régulateur de conductance transmembranaire de la mucoviscidose (CFTR), ainsi que des programmes de vaccins comprenant LUNAR-COV19 et LUNAR-FLU. Elle a conclu des partenariats de collaboration avec Vinbiocare Biotechnology Joint Stock Company pour la fabrication de vaccins contre la COVID-19 ; Janssen Pharmaceuticals, Inc. pour développer des candidats thérapeutiques à base d'acides nucléiques destinés au traitement du virus de l'hépatite B ; Ultragenyx Pharmaceutical, Inc. pour développer des candidats thérapeutiques à base d'ARNm pour des cibles de maladies rares ; CureVac AG pour développer des candidats thérapeutiques et vaccinaux à base d'ARNm pour diverses indications ; le Singapore Economic Development Board et la Duke-NUS Medical School pour développer le vaccin LUNAR-COV19 ; et Millennium Pharmaceuticals, Inc. pour découvrir des médicaments à base de siARN destinés au traitement de la stéatohépatite non alcoolique. La société a été fondée en 2013 et son siège social se trouve à San Diego, en Californie.
| Nom | Arcturus Therapeutics |
| PDG | Joseph E. Payne |
| Siège social | San Diego,
ca États-Unis |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 22/05/2013 |
| Employés | 109 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | ARCT |